DeepMed Research

CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3

Recruiting

Conditions: Alpha-Mannosidosis

Interventions: Drug: Velmanase Alfa

First Posted Date: 2023-12-28

Last Posted Date: 2025-05-16

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 5

Registration Number: NCT06184503

Locations: 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸
Greenwood Genetic Center, Greenwood, South Carolina, United States

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Phase 1

Recruiting

Conditions: Bronchiectasis

Interventions: Drug: CHF6333 Placebo
Drug: CHF6333

First Posted Date: 2023-12-12

Last Posted Date: 2024-01-22

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 45

Registration Number: NCT06166056

Locations: 🇬🇧
Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection, Cambridge, United Kingdom
🇬🇧
NHS Lothian, Edinburgh, United Kingdom
🇬🇧
The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital, Leeds, United Kingdom

and more 5 locations

Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

Phase 2

Active, not recruiting

Conditions: Uncontrolled Asthma

First Posted Date: 2023-09-08

Last Posted Date: 2025-03-28

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 464

Registration Number: NCT06029595

Locations: 🇦🇷
Site 032020 - Instituto Especialidades de la Salud Rosario - Clinica del Torax, Santa Fe, La, Argentina
🇦🇷
Site 032027- Centro de Medicina Respiratoria, Argentina, Argentina
🇦🇷
Site 032025 - Sala Mignaburu, Berazategui, Argentina

and more 184 locations

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

Phase 1

Completed

Conditions: Asthma

First Posted Date: 2023-06-12

Last Posted Date: 2024-10-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 69

Registration Number: NCT05898984

Locations: 🇧🇪
SGS Belgium NV - Clinical Pharmacology Unit, Edegem, Antwerpen, Belgium

Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance

Phase 1

Completed

Conditions: Mucociliary Clearance

Interventions: Other: Placebo formulated with HFA-134a propellant via pMDI
Other: Placebo formulated with HFA-152a propellant via pMDI

First Posted Date: 2023-05-25

Last Posted Date: 2024-11-11

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 20

Registration Number: NCT05875025

Locations: 🇬🇧
BDD Pharma - Bio-Imaging Centre, Glasgow, United Kingdom

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Phase 1

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: CHF5259
Drug: CHF5993 Placebo
Drug: CHF5993
Drug: Moxifloxacin 400mg

First Posted Date: 2023-04-26

Last Posted Date: 2023-10-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 95

Registration Number: NCT05830071

Locations: 🇺🇸
PAREXEL Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

Phase 2

Recruiting

Conditions: Fabry Disease

Interventions: Drug: PRX-102 1 mg/kg every 2 weeks
Drug: PRX-102 2 mg/kg every 4 weeks

First Posted Date: 2023-02-02

Last Posted Date: 2025-04-04

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 18

Registration Number: NCT05710692

Locations: 🇯🇵
Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan
🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵
University of the Ryukyu Hospital, Nishihara, Okinawa, Japan

and more 6 locations

PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Other: Observational retrospective data collection

First Posted Date: 2022-12-15

Last Posted Date: 2025-05-04

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 25000

Registration Number: NCT05652439

Locations: 🇬🇧
Clinical Practice Research Datalink (CPRD), London, United Kingdom

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF

Phase 1

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Biological: CHF10067 starting dose
Drug: Placebo
Biological: CHF10067 intermediate dose
Biological: CHF10067 high dose

First Posted Date: 2022-08-24

Last Posted Date: 2024-06-27

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 24

Registration Number: NCT05513950

Locations: 🇲🇰
PHI University Clinic of Pulmonology and Allergology, Skopje, North Macedonia
🇺🇦
Medical Center of Limited Liability Company "Arensia Exploratory Medicine", department of Clinical Trials, Kyiv, Ukraine
🇬🇧
Queen Elizabeth Hospital - NIHR Birmingham Clinical Research Facility - University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

and more 6 locations

A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo 152a
Drug: Placebo 134a

First Posted Date: 2022-07-25

Last Posted Date: 2024-10-11

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 25

Registration Number: NCT05472662

Locations: 🇬🇧
Medicine Evaluation Unit Limited, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy